Home › Compare › CRPFY vs ABBV
CRPFY yields 5.36% · ABBV yields 3.06%● Live data
📍 ABBV pulled ahead of the other in Year 1
Combined, CRPFY + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of CRPFY + ABBV for your $10,000?
Corporación Financiera Colombiana S.A. operates as a private financial institution in Columbia and Central America. It operates through Financial, Power and Gas, Infrastructure, Hospitality, Agroindustry, and Others segments. The company provides investment banking services, including merger and acquisition advisory services; capital market services, comprising issuance and placement of securities, such as bonds, securitizations, shares, commercial papers, bonds convertible into shares, etc.; and fundraising services. It also offers treasury products, consisting of legal tender, foreign currency, and investment and money market products; and commercial banking services. It also operates road concessions and hotels; produces and commercializes palm oil, palm kernel oil, palm kernel cake, technically specified rubber, certified rice seed, and bio-inputs; and manufactures synthetic fabrics, products specialized in providing shadow, and enclosure solutions under the Polisombra brand, as well as bonding and fastening media for agro-industrial and home use. In addition, the company operates 3,204 kms of gas pipeline; and distributes natural gas to approximately 3.72 million users. The company was founded in 1961 and is based in Bogotá, Colombia.
Full CRPFY Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.